![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, November 07, 2018 8:56:38 AM
November 07, 2018
SAINT LAURENT, Quebec, Nov. 07, 2018 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced the execution of a definitive license, development and supply agreement (the “Agreement”) with Tilray, Inc. (NASDAQ:TLRY) (“Tilray®”), a global leader in cannabis production and distribution. Pursuant to the Agreement, the two companies will co-develop and commercialize oral film products infused with adult-use and medical cannabis (“cannabis-infused VersaFilm™”), in anticipation of amended cannabis regulations that would allow adult-use consumers to purchase edible products in Canada.
Under the Agreement, IntelGenx and Tilray® will each fund 20% and 80% of the costs associated with the development of the cannabis-infused Versafilm™ products, respectively. IntelGenx will have the exclusive right to manufacture and supply the co-developed products to Tilray®, and will also receive a fixed single-digit royalty on net product sales. Tilray® will have the exclusive, worldwide marketing and distribution rights for the co-developed products.
In connection with the Agreement, the parties have also executed a subscription agreement pursuant to which Tilray® will make a strategic investment in IntelGenx by way of a non-brokered private placement (“Private Placement”). Pursuant to the Private Placement, Tilray® will purchase 1,428,571 common shares of IntelGenx at a price of US$0.70 per share for gross proceeds to IntelGenx of US$1 million. The price of US$0.70 per share, rather than the US$0.80 per share price which had been proposed in the non-binding letter of intent between the parties and announced on September 20, 2018, represents the price per unit paid by investors under IntelGenx’s recent public offering. IntelGenx intends to use the proceeds from the Private Placement for cannabis-infused VersaFilm™ product development in connection with the Agreement. The Private Placement is expected to close on or about November 9, 2018, subject to approval by the TSX Venture Exchange and satisfaction of customary closing conditions.
“With IntelGenx having the only Health Canada compliant and licensed facility for pharmaceutical oral film manufacturing, we are excited to establish this important partnership with Tilray, a global leader in the medical and adult-use cannabis industry, and a company that shares our enthusiasm about the prospects for oral thin film delivery,” said Dr. Horst G. Zerbe, President and CEO of IntelGenx. “Both companies see a world where innovative, pharmaceutical-grade cannabis products are made available to adult consumers and patients, and we are looking forward to working with Tilray to make that a reality.”
“Over the long-term, we believe a significant portion of the global cannabis market will be focused on non-combustible products,” said Woody Pastorius, Chief Revenue Officer of Tilray®. “Through this partnership, we look forward to co-developing oral film products infused with cannabis that we intend to market and distributed in Canada and other markets around the world as regulations permit.”
Recent IGXT News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 08:00:19 PM
- Form 1-A-W - Withdrawal of offering statement [Regulation A] • Edgar (US Regulatory) • 05/24/2024 07:49:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2024 12:00:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 08:16:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:00:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 10:25:33 PM
- Form 253G2 - • Edgar (US Regulatory) • 02/20/2024 07:07:33 PM
- Form QUALIF - Notice of Qualification [Regulation A] • Edgar (US Regulatory) • 02/20/2024 05:15:08 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 10:22:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 09:12:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 09:12:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 08:58:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 08:56:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 08:56:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 08:55:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 08:52:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 08:51:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 08:50:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 08:48:53 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 12/11/2023 09:16:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/04/2023 01:26:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/28/2023 09:18:42 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:10:11 PM
FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM